Phio Pharmaceuticals financials
$1.03+1.98%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | — | $21.0K | $138.0K |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — | — | $21.0K | $138.0K |
| Gross margin | — | — | — | — | — | — | 100.0% | 100.0% |
| Operating income | -$9.2M | -$7.4M | -$10.8M | -$11.5M | -$13.5M | -$8.8M | -$9.0M | -$7.4M |
| Net income | -$8.7M | -$7.2M | -$10.8M | -$11.5M | -$13.3M | -$8.8M | -$8.9M | -$7.4M |
| Net margin | — | — | — | — | — | — | −42419.0% | −5333.3% |
| Diluted EPS | $-1.45 | $-9.08 | $-46.76 | $-90.90 | $-111.87 | $-207.36 | $-2087.64 | $-6205.68 |
| EBITDA | -$9.2M | -$7.4M | -$10.6M | -$11.4M | -$13.4M | -$8.7M | -$8.9M | -$7.3M |
| Operating cash flow | -$8.0M | -$7.1M | -$10.7M | -$12.1M | -$11.9M | -$8.8M | -$8.6M | -$7.5M |
| Free cash flow | -$8.0M | -$7.1M | -$10.8M | -$12.3M | -$11.9M | -$8.8M | -$8.7M | -$7.5M |
| Diluted shares | 6.0M | 0.8M | 0.2M | 0.1M | 0.1M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $21.0M | $5.4M | $8.5M | $11.8M | $24.1M | $14.2M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $231.0K |
| Total assets | $21.5M | $5.7M | $9.4M | $12.8M | $25.2M | $15.7M |
| Total liabilities | $1.3M | $1.0M | $1.6M | $2.0M | $3.2M | $2.7M |
| Shareholders' equity | $20.1M | $4.7M | $7.7M | $10.8M | $21.9M | $13.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology